Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 3701 - 3725 of 4240 in total
Dabocemagene autoficel is an ex vivo, autologous cell-based gene therapy. It comprises autologous dermal fibroblasts genetically modified to express functional type VII collagen. Developed by Castle Creek Biosciences Inc., dabocemagene autoficel is being investigated for the treatment of dystrophic epidermolysis bullosa.
Investigational
Yersinia pestis 195/p antigen (formaldehyde inactivated) is under investigation in clinical trial NCT02596308 (Immunogenicity and Safety of Subunit Plague Vaccine).
Investigational
Experimental
Tetrafluoroborate is under investigation in clinical trial NCT02907073 (Positron Emission Tomography (PET) Imaging Studies With NIS Reporter).
Investigational
MK-4541 is a 4-azasteroid and a selective androgen receptor modulator (SARM). MK-4541 acts as a dual selective SARM and is both a potent androgen receptor antagonist and a 5α-reductase inhibitor.
Investigational
Investigational
PEP0101 is a nanocomplex consisting of elastin-like polypeptides and a small interfering RNA (siRNA) designed to down-regulate the expression of EVI1 oncogene in cancer cells.
Investigational
Danburstotug is under investigation in clinical trial NCT04809012 (Study of STI-3031 in Patients With Selected Relapsed or Refractory Solid Tumors).
Investigational
Lilotomab is under investigation in clinical trial NCT01796171 (A Phase 1/2 Study of Betalutin for Treatment of Relapsed Non-hodgkin Lymphoma).
Investigational
Experimental
Investigational
RR001 is an investigational gene therapy consisting of autologous human adipose perivascular stromal cells genetically modified to secrete soluble tumour necrosis factor-related apoptosis-inducing ligand (AD-PC sTRAIL).
Investigational
Displaying drugs 3701 - 3725 of 4240 in total